drugset / Trial / NCT04939311
Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
Phase 1/2
Withdrawn
Priscilla Hsue, MD
University of California, Los Angeles · collabUniversity of Utah · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-07-01
- Completion
- 2027-07-01
Outcome
Outcome not reported
Stopped (Business): “Funding for this trial has not been established.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VB-201 | Small molecule | 80 mg | Oral |